Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-28
Target enrollment:
Participant gender:
Summary
This dose escalation and dose expansion study is to evaluate and characterize the
tolerability, safety, pharmacokinetics and efficacy profile of single agent KY-0118 in
Locally Advanced or Metastatic Solid Tumor Patients.